Product NDC: | 0093-5703 |
Proprietary Name: | BUPROBAN |
Non Proprietary Name: | BUPROPION HYDROCHLORIDE |
Active Ingredient(s): | 150 mg/1 & nbsp; BUPROPION HYDROCHLORIDE |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, EXTENDED RELEASE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0093-5703 |
Labeler Name: | TEVA Pharmaceuticals USA Inc |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA075914 |
Marketing Category: | ANDA |
Start Marketing Date: | 20040527 |
Package NDC: | 0093-5703-01 |
Package Description: | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0093-5703-01) |
NDC Code | 0093-5703-01 |
Proprietary Name | BUPROBAN |
Package Description | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0093-5703-01) |
Product NDC | 0093-5703 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | BUPROPION HYDROCHLORIDE |
Dosage Form Name | TABLET, EXTENDED RELEASE |
Route Name | ORAL |
Start Marketing Date | 20040527 |
Marketing Category Name | ANDA |
Labeler Name | TEVA Pharmaceuticals USA Inc |
Substance Name | BUPROPION HYDROCHLORIDE |
Strength Number | 150 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |